by Seth J. Baum MD PCSK9 inhibitors are the most significant advance in the management of elevated cholesterol in the last 3 decades. These injectable medications are indisputably revolutionary: They provide intensive and predictable reduction of LDL cholesterol in even our most difficult-to-treat patients. So, you would think that insurance providers would embrace them. Not…

Read More

by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol lowering drugs that were FDA approved in the summer of 2015. Insurance providers had viewed these costly medications as a potentially grave threat to their…

Read More

by Seth J. Baum, MD I’ve written extensively about the mounting burden borne by doctors and patients. Looking beyond the escalating regulatory time-drains beleaguering doctors throughout the nation we see that simply prescribing medications for our patients has become a tribulation. Why this is so and what ramifications ensue, deserves exploration. Thus I have written…

Read More